Rexahn cancer drug safe so far in Phase I study, shares jump


Rexahn's (RNN) Supinoxin (RX-5902) has so far shown to be "safe and well-tolerated" in an ongoing Phase I trial of patients with solid cancer tumors, with no drug-related side-effects reported.

A fourth dosing cycle has been initiated following the completion of three cycles.

In animal testing, treatment with Supinoxin resulted in a significant reduction in tumor growth.

Shares jump 14.9%. (PR)

Comments (4)
  • mreits4ever
    , contributor
    Comments (123) | Send Message
     
    Take that Adam !
    11 Mar 2014, 08:52 AM Reply Like
  • massawe
    , contributor
    Comments (8) | Send Message
     
    boooyahhhh!!!
    11 Mar 2014, 09:03 AM Reply Like
  • GrowthGeek
    , contributor
    Comments (2669) | Send Message
     
    Supinoxin will be RNN's meal ticket. Archexin may or may not go anywhere but Supinoxin looks fantastic. Someone stick a pin in Adam F. please, but look out for the hot air expulsion in doing so.
    11 Mar 2014, 11:19 AM Reply Like
  • jeepman58
    , contributor
    Comments (225) | Send Message
     
    From the press release:
    "In preclinical studies, Supinoxin has been shown to inhibit proliferation of cancer cells in 18 human cancer cell lines including breast, colon, pancreas, ovarian, and stomach cancers, and showed potent activity in drug-resistant cancer cells. In an animal model, where human cancer cells from melanoma, pancreas, renal or ovarian cancers were grafted into animals, treatment with Supinoxin resulted in a significant reduction in tumor growth."

     

    Early results in the safety and efficacy clinical trial show "no drug related adverse events have been reported" and 25, 50, and 100mg doses have not reached Maximum Tolerated Dose.

     

    And preclinical studies show inhibiting proliferation of cancer cells in 18 human cancer cell lines.

     

    This seems to be a situation where good news is good news. Especially as the clinical P1 "is consistent with preclinical studies.

     

    Congratulations to the Rexahn researchers and best wishes for all the patients.
    11 Mar 2014, 12:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs